FREMONT, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018 , as well as recent business highlights.
FREMONT, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will participate in a panel titled “Drug Delivery” to be held on Monday,
FREMONT, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss financial results for the fourth quarter
Long-term one-year dosing reaffirmed well-tolerated safety profile Qtrypta showed robust and rapid relief of migraine pain, an effect that was consistent throughout the chronic treatment period NDA submission expected in Q4 2019 for the first intracutaneous delivery system FREMONT, Calif. , Feb.
FREMONT, Calif. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase 2/3 (ZOTRIP) study in Headache: The Journal
FREMONT, Calif. , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais , M.D., J.D. to its board of directors. Dr.
FREMONT, Calif. , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has conditionally accepted the proposed brand name Qtrypta™ for
Selected a contract manufacturer for commercial launch of M207 Completed first required data set in long-term safety study of M207 Appointed Greg Kitchener as Chief Financial Officer FREMONT,Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
FREMONT, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET .
FREMONT, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 evaluable subjects have completed their six month visit in the M207-ADAM study (the "Study"), a
